Titan Pharmaceuticals
TTNP
TTNP was delisted on the 1st of October, 2025.
23 hedge funds and large institutions have $799K invested in Titan Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 4 increasing their positions, reducing their positions, and 5 closing their positions.
80% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 5
21% more capital invested
Capital invested by funds: $660K → $799K (+$139K)
21% more funds holding
Funds holding: 19 → 23 (+4)
0% less ownership
Funds ownership: 0.01% → 0% (-0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PAG
Private Advisor Group
Morristown,
New Jersey
|
+$60.6K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$46.8K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$30.1K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$20.8K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$11.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$249K |
| 2 |
ECM
ETrade Capital Management
Arlington,
Virginia
|
-$14K |
| 3 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$10K |
| 4 |
RJFSA
Raymond James Financial Services Advisors
St. Petersburg,
Florida
|
-$9K |
| 5 |
HighTower Advisors
Chicago,
Illinois
|
-$5K |
TTNP Hedge Fund Activity: Q2 2020 in Review
23 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q2 2020, worth a combined $799K — up 21% from $660K a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new TTNP positions and 5 closed out — a net gain of 4 holders — while 4 added to existing stakes and 0 trimmed.
The largest buyer was Private Advisor Group, opening a new position worth an estimated $60.6K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $249K sold.
- 23 institutional investors held Titan Pharmaceuticals (TTNP) as of Q2 2020, up from 19 in Q1 2020.
- Funds reported $799K of Titan Pharmaceuticals stock for Q2 2020, up 21% quarter-over-quarter.
- 9 funds opened new Titan Pharmaceuticals positions in Q2 2020 and 5 closed out, a net change of +4 holders.
- The largest Titan Pharmaceuticals buyer in Q2 2020 was Private Advisor Group, an estimated $60.6K added.
- The largest Titan Pharmaceuticals seller in Q2 2020 was Susquehanna International Group, an estimated $249K sold.
Based on aggregated 13F filings for Q2 2020.